USFDA approval of Avastin biosimilar Mvasi

The USFDA is approved a version of Avastin, a blockbuster chemotherapy made by Genentech that brought in $6.7 billion in sales in 2016.

Innovator Biopharmaceutical: Roche AG’s Avastin.
Amgen Inc. and Allergan plc’s biosimilar version brand name is Mvasi.

Note: It was not approved as an interchangeable, meaning pharmacists can’t automatically switch patients taking Avastin to Mvasi.